Affiliation:
1. Department of Advanced Biomedical Sciences, Federico II School of Medicine, 80128 Naples, Italy
2. National Research Council (CNR), Institute of Biostructures and Bioimaging, 80145 Naples, Italy
3. Federico II University Hospital, 80128 Naples, Italy
Abstract
Stereotactic radiation therapy (SRT) is a proven effective treatment for brain metastases (BM); however, symptomatic radiation necrosis (RN) is a late effect that may impact on patient’s quality of life. The aim of our study was to retrospectively evaluate survival outcomes and characterize the occurrence of RN in a cohort of BM patients treated with ablative SRT at Federico II University Hospital. Clinical and dosimetric factors of 87 patients bearing a total of 220 BMs treated with SRT from 2016 to 2022 were analyzed. Among them, 46 patients with 127 BMs having clinical and MRI follow-up (FUP) ≥ 6 months were selected for RN evaluation. Dosimetric parameters of the uninvolved brain (brain without GTV) were extracted. The crude local control was 91% with neither clinical factors nor prescription dose correlating with local failure (LF). At a median FUP of 9 (1–68) months, the estimated median overall survival (OS), progression-free survival (PFS), and brain progression-free survival (bPFS) were 16, 6, and 9 months, respectively. The estimated OS rates at 1 and 3 years were 59.8% and 18.3%, respectively; bPFS at 1 and 3 years was 29.9% and 13.5%, respectively; PFS at 1 and 3 years was 15.7% and 0%, respectively; and local failure-free survival (LFFS) at 1 and 3 years was 87.2% and 83.8%, respectively. Extracranial disease status was an independent factor related to OS. Fourteen (30%) patients manifested RN. At multivariate analysis, adenocarcinoma histology, left location, and absence of chemotherapy were confirmed as independent risk factors for any-grade RN. Nine (20%) patients developed symptomatic (G2) RN, which improved or stabilized after 1–16 months of steroid therapy. With prompt recognition and, when necessary, medical therapy, RN radiological and clinical amelioration can be obtained.
Reference40 articles.
1. The Evolving Landscape of Brain Metastasis;Valiente;Trends Cancer,2018
2. EANO–ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Patients with Brain Metastasis from Solid Tumours;Guckenberger;Ann. Oncol.,2021
3. Prognostic scores for brain metastasis patients: Use in clinical practice and trial design;Venur;Chin. Clin. Oncol.,2015
4. Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: A retrospective cohort study;Liu;Cancer Biol. Med.,2022
5. Significance of surgical resection for the treatment of multiple brain metastases;Iwadate;Anticancer. Res.,2000